首页> 美国卫生研究院文献>Influenza and Other Respiratory Viruses >Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009–2010 H1N1 pandemic: summary of an ecological study
【2h】

Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009–2010 H1N1 pandemic: summary of an ecological study

机译:在2009-2010年H1N1大流行期间降低甲型流感(H1N1)死亡率相关的神经氨酸酶抑制剂的供应:一项生态研究摘要

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

When the influenza A (H1N1) pandemic spread across the globe from April 2009 to August 2010, many WHO Member States used antiviral drugs, specifically neuraminidase inhibitors (NAIs) oseltamivir and zanamivir, to treat influenza patients in critical condition. Antivirals have been found to be effective in reducing severity and duration of influenza illness, and likely reduce morbidity; however, it is unclear whether NAIs used during the pandemic reduced H1N1 mortality. To assess the association between antivirals and influenza mortality, at an ecologic level, country‐level data on supply of oseltamivir and zanamivir were compared to laboratory‐confirmed H1N1 deaths (per 100 000 people) from July 2009 to August 2010 in 42 WHO Member States. From this analysis, it was found that each 10% increase in kilograms of oseltamivir, per 100 000 people, was associated with a 1·6% reduction in H1 style="fixed-case">N1 mortality over the pandemic period [relative rate ( style="fixed-case">RR) = 0·84 per log increase in oseltamivir supply]. Each 10% increase in kilogram of active zanamivir, per 100 000, was associated with a 0·3% reduction in style="fixed-case">H1 style="fixed-case">N1 mortality ( style="fixed-case">RR = 0·97 per log increase). While limitations exist in the inference that can be drawn from an ecologic evaluation, this analysis offers evidence of a protective relationship between antiviral drug supply and influenza mortality and supports a role for influenza antiviral use in future pandemics. This article summarises the original study described previously, which can be accessed through the following citation: Miller style="fixed-case">PE, Rambachan A, Hubbard style="fixed-case">RJ, Li J, Meyer style="fixed-case">AE, et al. (2012) Supply of Neuraminidase Inhibitors Related to Reduced Influenza A (H1N1) Mortality during the 2009–2010 H1N1 Pandemic: An Ecological Study. style="fixed-case">PLoS style="fixed-case">ONE 7(9): e43491.
机译:2009年4月至2010年8月,当甲型流感(H1N1)大流行在全球蔓延时,许多世卫组织会员国使用抗病毒药物,特别是神经氨酸酶抑制剂奥司他韦和扎那米韦来治疗危重状态的流感患者。已发现抗病毒药可有效降低流感疾病的严重程度和持续时间,并可能降低发病率。然而,尚不清楚大流行期间使用的NAI是否降低H1N1死亡率。为了评估抗病毒药物与流感病毒死亡率之间的关系,在生态学层面上,比较了2009年7月至2010年8月世卫组织42个会员国的国家级奥司他韦和扎那米韦供应数据与实验室确诊的H1N1死亡(每10万例) 。从该分析中发现,每100万人中的奥司他韦公斤每增加10%,则H1 style =“ fixed-case”> N 1死亡率降低1·6%在大流行期间[相对比率( style =“ fixed-case”> RR )= 0·84,每log增加一次奥司他韦的供应量”。每100 000公斤有效扎那米韦每增加10%, style =“ fixed-case”> H 1 style =“ fixed-case”> N 1死亡率( style =“ fixed-case”> RR = 0·97 / log增加)。虽然可以从生态评估中得出的推论存在局限性,但该分析提供了抗病毒药物供应与流感病毒死亡率之间的保护性关系的证据,并支持了流感病毒在未来大流行中使用抗病毒药的作用。本文总结了先前描述的原始研究,可以通过以下引用进行访问:Miller style =“ fixed-case”> PE ,Rambachan A,Hubbard style =“ fixed-case”> RJ ,Li J,Meyer style =“ fixed-case”> AE 等。 (2012)与2009-2010年H1N1大流行期间甲型流感(H1N1)死亡率降低相关的神经氨酸酶抑制剂的供应:一项生态研究。 style =“ fixed-case”> PL oS style =“ fixed-case”> ONE 7(9):e43491。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号